We are excited to reveal the shortlist for the 2026 Health Tech Company of the Year Award.
The award is one of eight to feature at the forth-annual Health Tech World Awards.
The Health Tech Company of the Year Award recognises exception companies that has demonstrate outstanding leadership, innovation, and impact in the health tech sector.
The winner will have demonstated excellence across all dimensions of their business, from groundbreaking product development and robust growth to meaningful improvements in healthcare delivery and unwavering commitment to their mission.
About the sponsor
As one of the world’s largest independent global communications and creative agencies, Ruder Finn has defined and redefined PR for more than 70 years, shaping communications that move industry-defining brands, companies and leaders from what’s now to what’s next.
Its clients share the same mindset.
From developing breakthrough science and transformative technologies to building authentic bridges across diverse communities, their visions are laser focused on making change for the better.
What happens next?
The shortlisted entries will be judged be a representative from company sponsor, Ruder Finn.
The winner will be announced at a virtual event on October 28.
Congratulations to the shortlist and thank you to everyone who took the time to enter.
Health Tech Company of the Year Shortlist
Cera is tackling the challenges of an ageing population through AI, robotics and data-driven home healthcare.
In 2025-26, it became a unicorn, reached around £500m in annualised revenue and expanded its AI, robotics and data businesses.
Its technology is powered by millions of monthly home care visits, helping to reduce hospitalisations, improve care capacity and deliver significant savings for the NHS and government.
Cera is also addressing the care workforce shortage through large-scale recruitment and training, while developing robotics and AI solutions to improve productivity and support more people to live independently at home.
FibroFind is transforming drug development through its patented bioreactor technology, which keeps living human tissue functional outside the body for days to weeks.
Its platform enables pharmaceutical companies to test candidate medicines directly on human liver, lung, kidney, heart, synovium and skin tissue before they reach clinical trials.
The technology is already being adopted at commercial scale, with major pharmaceutical companies including GSK significantly increasing their use of FibroFind’s platform.
Semble is an interoperable electronic health record (EHR) and practice management platform designed to support healthcare providers of all sizes, from individual consultants to multi-site groups.
Founded by Christoph Lippuner and Mikael Landau, Semble was born from their firsthand experiences of disconnected healthcare systems, which fostered a deep sense of empathy for healthcare teams and a drive to address these challenges.
Supporting more than 10 million patients across Europe to date and automating over 3 million admin tasks in the past year, Semble is setting a new standard for healthcare technology by making care more connected, coordinated and scalable.
